S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:ILMN

Illumina Stock Forecast, Price & News

$350.66
+4.66 (+1.35 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$343.40
Now: $350.66
$350.99
50-Day Range
$292.70
MA: $311.62
$346.00
52-Week Range
$196.78
Now: $350.66
$404.20
Volume1.17 million shs
Average Volume1.28 million shs
Market Capitalization$51.20 billion
P/E Ratio81.36
Dividend YieldN/A
Beta1.1
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Illumina logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500
Employees7,700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.54 billion
Cash Flow$9.50 per share
Book Value$32.19 per share

Profitability

Net Income$1.00 billion

Miscellaneous

Market Cap$51.20 billion
Next Earnings Date2/3/2021 (Estimated)
OptionableOptionable
$350.66
+4.66 (+1.35 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Illumina (NASDAQ:ILMN) Frequently Asked Questions

How has Illumina's stock been impacted by COVID-19?

Illumina's stock was trading at $246.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ILMN stock has increased by 42.5% and is now trading at $350.66.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Illumina?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 3 sell ratings, 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Illumina
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Illumina?

Wall Street analysts have given Illumina a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Illumina wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Illumina
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings results on Thursday, October, 29th. The life sciences company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.77 by $0.25. The life sciences company earned $794 million during the quarter, compared to the consensus estimate of $713.97 million. Illumina had a net margin of 19.70% and a return on equity of 15.93%. Illumina's quarterly revenue was down 12.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.93 EPS.
View Illumina's earnings history
.

What price target have analysts set for ILMN?

17 analysts have issued 12-month price targets for Illumina's stock. Their forecasts range from $280.00 to $400.00. On average, they expect Illumina's share price to reach $322.12 in the next twelve months. This suggests that the stock has a possible downside of 8.1%.
View analysts' price targets for Illumina
.

Are investors shorting Illumina?

Illumina saw a increase in short interest in November. As of November 15th, there was short interest totaling 4,420,000 shares, an increase of 8.9% from the October 31st total of 4,060,000 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is currently 2.9 days. Approximately 3.0% of the shares of the stock are sold short.
View Illumina's Short Interest
.

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), The Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Who are Illumina's key executives?

Illumina's management team includes the following people:
  • Mr. Francis A. deSouza, CEO, Pres & Director (Age 49)
  • Mr. Sam A. Samad, CFO & Sr. VP (Age 50, Pay $626.7k)
  • Dr. Joydeep Goswami, Sr. VP of Corp. Devel. & Strategic Planning (Age 49, Pay $384.38k)
  • Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 49, Pay $864.07k)
  • Mr. Robert P. Ragusa, Sr. VP of Global Quality & Operations (Age 60)
  • Ms. Karen K. McGinnis, VP & Chief Accounting Officer (Age 53)
  • Dr. Alexander Aravanis M.D., Ph.D., Sr. VP & Chief Technology Officer
  • Mr. Steve Phillpott, Sr. VP & Chief Information Officer
  • Ms. Juliet Cunningham, VP of Investor Relations
  • Mr. Charles E. Dadswell, Sr. VP, Gen. Counsel & Sec. (Age 61)

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sands Capital Management LLC (2.11%), Massachusetts Financial Services Co. MA (1.07%), Harding Loevner LP (1.01%), Jackson Square Partners LLC (0.87%), Sustainable Growth Advisers LP (0.81%) and ARK Investment Management LLC (0.67%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina
.

Which institutional investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Jennison Associates LLC, First Hawaiian Bank, Nikko Asset Management Americas Inc., Sands Capital Management LLC, Natixis, Federated Hermes Inc., and Envestnet Asset Management Inc.. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina
.

Which institutional investors are buying Illumina stock?

ILMN stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Harding Loevner LP, Sarasin & Partners LLP, Arrowstreet Capital Limited Partnership, DAVENPORT & Co LLC, Sustainable Growth Advisers LP, Alleghany Corp DE, and Massachusetts Financial Services Co. MA.
View insider buying and selling activity for Illumina
.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $350.66.

How big of a company is Illumina?

Illumina has a market capitalization of $51.20 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.